http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 08:00:34 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/AEON+Biopharma+prices+%2413.75M+public+offering+with+milestone+warrants/26765079.html <p>AEON Biopharma, Inc. (NYSE American: AEON) has priced an underwritten public offering expected to raise approximately $13.75 million in gross proceeds, with the potential for up to $43.3 million total if accompanying milestone warrants are fully exercised in cash, according to a press release.</p> <p>The offering consists of 42,688,606 shares of common stock, or pre-funded warrants in lieu thereof, priced at $0.3221 per share. Each share is accompanied by a two-year milestone warrant and a five-year milestone warrant, each to purchase one share of common stock. The two-year warrants carry an exercise price of $0.3221 per share, while the five-year warrants http://www.streetinsider.com/Equity+Offerings/AEON+Biopharma+prices+%2413.75M+public+offering+with+milestone+warrants/26765079.html Tue, 14 Jul 2026 08:00:34 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Equity+Offerings/AEON+Biopharma+prices+%2413.75M+public+offering+with+milestone+warrants/26765079.html <p>AEON Biopharma, Inc. (NYSE American: AEON) has priced an underwritten public offering expected to raise approximately $13.75 million in gross proceeds, with the potential for up to $43.3 million total if accompanying milestone warrants are fully exercised in cash, according to a press release.</p> <p>The offering consists of 42,688,606 shares of common stock, or pre-funded warrants in lieu thereof, priced at $0.3221 per share. Each share is accompanied by a two-year milestone warrant and a five-year milestone warrant, each to purchase one share of common stock. The two-year warrants carry an exercise price of $0.3221 per share, while the five-year warrants http://www.streetinsider.com/Equity+Offerings/AEON+Biopharma+prices+%2413.75M+public+offering+with+milestone+warrants/26765079.html Tue, 14 Jul 2026 08:00:34 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Equity+Offerings/AEON+Biopharma+prices+%2413.75M+public+offering+with+milestone+warrants/26765079.html <p>AEON Biopharma, Inc. (NYSE American: AEON) has priced an underwritten public offering expected to raise approximately $13.75 million in gross proceeds, with the potential for up to $43.3 million total if accompanying milestone warrants are fully exercised in cash, according to a press release.</p> <p>The offering consists of 42,688,606 shares of common stock, or pre-funded warrants in lieu thereof, priced at $0.3221 per share. Each share is accompanied by a two-year milestone warrant and a five-year milestone warrant, each to purchase one share of common stock. The two-year warrants carry an exercise price of $0.3221 per share, while the five-year warrants http://www.streetinsider.com/Equity+Offerings/AEON+Biopharma+prices+%2413.75M+public+offering+with+milestone+warrants/26765079.html Tue, 14 Jul 2026 08:00:34 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Equity+Offerings/AEON+Biopharma+prices+%2413.75M+public+offering+with+milestone+warrants/26765079.html <p>AEON Biopharma, Inc. (NYSE American: AEON) has priced an underwritten public offering expected to raise approximately $13.75 million in gross proceeds, with the potential for up to $43.3 million total if accompanying milestone warrants are fully exercised in cash, according to a press release.</p> <p>The offering consists of 42,688,606 shares of common stock, or pre-funded warrants in lieu thereof, priced at $0.3221 per share. Each share is accompanied by a two-year milestone warrant and a five-year milestone warrant, each to purchase one share of common stock. The two-year warrants carry an exercise price of $0.3221 per share, while the five-year warrants http://www.streetinsider.com/Equity+Offerings/AEON+Biopharma+prices+%2413.75M+public+offering+with+milestone+warrants/26765079.html Tue, 14 Jul 2026 08:00:34 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html <p align="justify">IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.</p> <p http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html Tue, 14 Jul 2026 08:00:00 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html <p align="justify">IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.</p> <p http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html Tue, 14 Jul 2026 08:00:00 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html <p align="justify">IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.</p> <p http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html Tue, 14 Jul 2026 08:00:00 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html <p align="justify">IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.</p> <p http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html Tue, 14 Jul 2026 08:00:00 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html <p align="justify">IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.</p> <p http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html Tue, 14 Jul 2026 08:00:00 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html <p align="justify">IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.</p> <p http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html Tue, 14 Jul 2026 08:00:00 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html <p align="justify">IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.</p> <p http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html Tue, 14 Jul 2026 08:00:00 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html <p align="justify">IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.</p> <p http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Pricing+of+Upsized+%2413.75+Million+Public+Offering+with+Accompanying+Milestone+Warrants+Providing+Potential+for+Additional+Future+Funding%C2%A0/26764996.html Tue, 14 Jul 2026 08:00:00 -0400 A.26693277 AEON O.21906544 O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Thunen+Shelley+B/26674373.html si-local-file:///var/storage/secattach/20260622/26674373.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Thunen+Shelley+B/26674373.html Mon, 22 Jun 2026 18:22:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Thunen+Shelley+B/26674373.html si-local-file:///var/storage/secattach/20260622/26674373.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Thunen+Shelley+B/26674373.html Mon, 22 Jun 2026 18:22:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+PALMISANO+ROBERT+J/26674372.html si-local-file:///var/storage/secattach/20260622/26674372.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+PALMISANO+ROBERT+J/26674372.html Mon, 22 Jun 2026 18:21:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+PALMISANO+ROBERT+J/26674372.html si-local-file:///var/storage/secattach/20260622/26674372.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+PALMISANO+ROBERT+J/26674372.html Mon, 22 Jun 2026 18:21:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Forth+Marc/26674362.html si-local-file:///var/storage/secattach/20260622/26674362.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Forth+Marc/26674362.html Mon, 22 Jun 2026 18:19:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Forth+Marc/26674362.html si-local-file:///var/storage/secattach/20260622/26674362.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Forth+Marc/26674362.html Mon, 22 Jun 2026 18:19:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+FISCHER+JOST/26674360.html si-local-file:///var/storage/secattach/20260622/26674360.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+FISCHER+JOST/26674360.html Mon, 22 Jun 2026 18:18:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+FISCHER+JOST/26674360.html si-local-file:///var/storage/secattach/20260622/26674360.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+FISCHER+JOST/26674360.html Mon, 22 Jun 2026 18:18:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Carter+Eric+G/26674354.html si-local-file:///var/storage/secattach/20260622/26674354.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Carter+Eric+G/26674354.html Mon, 22 Jun 2026 18:16:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Carter+Eric+G/26674354.html si-local-file:///var/storage/secattach/20260622/26674354.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jun+17++Filed+by%3A+Carter+Eric+G/26674354.html Mon, 22 Jun 2026 18:16:00 -0400 AEON O.49558857 http://www.streetinsider.com/Corporate+News/AEON+Biopharma+presents+ABP-450+biosimilar+data+at+headache+conference/26602374.html <p>AEON Biopharma Inc. (NYSE American: AEON) presented analytical and functional data comparing its ABP-450 candidate to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society in Orlando, Florida.</p><p>The data showed LC-MS peptide mapping demonstrated 93%-99% sequence coverage across the core neurotoxin and accessory proteins, with no variant peptides observed between ABP-450 and BOTOX. In the LD50 potency assay, all ABP-450 lots fell within predefined equivalence criteria established from BOTOX reference results.</p><p>Chad K. Oh, AEON's Chief Medical Officer, presented the poster titled "Establishing Structural and Functional Comparability Between ABP-450 and OnabotulinumtoxinA to Support Biosimilarity" on June 4, 2026.</p><p>The http://www.streetinsider.com/Corporate+News/AEON+Biopharma+presents+ABP-450+biosimilar+data+at+headache+conference/26602374.html Thu, 04 Jun 2026 07:03:07 -0400 AEON http://www.streetinsider.com/FDA/AEON+Biopharma+presents+ABP-450+biosimilar+data+at+headache+conference/26602374.html <p>AEON Biopharma Inc. (NYSE American: AEON) presented analytical and functional data comparing its ABP-450 candidate to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society in Orlando, Florida.</p><p>The data showed LC-MS peptide mapping demonstrated 93%-99% sequence coverage across the core neurotoxin and accessory proteins, with no variant peptides observed between ABP-450 and BOTOX. In the LD50 potency assay, all ABP-450 lots fell within predefined equivalence criteria established from BOTOX reference results.</p><p>Chad K. Oh, AEON's Chief Medical Officer, presented the poster titled "Establishing Structural and Functional Comparability Between ABP-450 and OnabotulinumtoxinA to Support Biosimilarity" on June 4, 2026.</p><p>The http://www.streetinsider.com/FDA/AEON+Biopharma+presents+ABP-450+biosimilar+data+at+headache+conference/26602374.html Thu, 04 Jun 2026 07:03:07 -0400 AEON http://www.streetinsider.com/Press+Releases/AEON+Biopharma+to+Present+Data+Demonstrating+Structural+and+Functional+Comparability+of+ABP-450+to+BOTOX%C2%AE+at+the+68th+Annual+Scientific+Meeting+of+the+American+Headache+Society/26602293.html <p align="justify">IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the presentation of new analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society (“AHS”), being held June 4-7, 2026 in Orlando, Florida. The poster is being presented by Chad K. Oh, M.D., AEON&apos;s Chief Medical Officer.  </p> <p align="justify">The data being presented today builds http://www.streetinsider.com/Press+Releases/AEON+Biopharma+to+Present+Data+Demonstrating+Structural+and+Functional+Comparability+of+ABP-450+to+BOTOX%C2%AE+at+the+68th+Annual+Scientific+Meeting+of+the+American+Headache+Society/26602293.html Thu, 04 Jun 2026 07:00:00 -0400 AEON O.49558857